MedTrace Logo

WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data

NCT03210285 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2018-07-23

No results posted yet for this study

Summary

Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults. The aim is to gain insight into the complete genome of the NF2 associated VS compared to sporadic VS (control group). These data are to be correlated with the clinic, ie the auditory function (audiogram, acoustically evoked potentials) and the clinical picture as well as the tumor growth rate and general data such as sex, age, side, etc.

Conditions

  • Neurofibromatosis Type 2
  • Vestibular Schwannoma
  • Acoustic Neuroma

Interventions

DIAGNOSTIC_TEST

Whole exome sequencing

Whole exome sequencing

Sponsors & Collaborators

  • National Center for Tumor Diseases, Heidelberg

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Martin Schuhmann, Prof. Dr. · University Hospital Tübingen

Eligibility

Min Age
1 Day
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2018-04-01
Completion
2018-07-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03210285 on ClinicalTrials.gov